Fig. 6

Dual targeting of NAT10 and EGFR effectively inhibited the proliferation of wild-type KRAS CRC cells. A, B. EdU assays were used to verify the cooperative effects of Remodelin and cetuximab in KRAS wild-type CRC cells. C. Synergy diagram of Remodelin and cetuximab, calculated with the online SynergyFinder software. SW48 cells were treated with different concentrations of reagents at various concentrations (Remodelin: 0, 10, 20, 40, 80 µM; cetuximab: 0, 10, 20, 40, 80 µM) for 24 h. Relative cell viability was subsequently measured. ZIP values were simulated using zero interaction potency model analysis. D. Representative images of subcutaneous tumors in the indicated groups. E. Tumor volumes were measured every 3 days. F. Tumor weights are expressed as the mean ± SD of five mice. G. Representative images of IHC staining with an anti-Ki67 antibody in tumors formed in the indicated groups. The data are representative of three independent experiments and presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, calculated using two-tailed unpaired Student’s t-tests